MedTrace Logo

Rotating Pazopanib and Everolimus to Avoid Resistance

NCT01408004 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2014-07-16

No results posted yet for this study

Summary

In this study will be examined whether alternating treatment between two classes of drugs (TKI's and m-TOR inhibitors) postpones or prevents drug resistance in patients with renal cancer.

Conditions

  • Clear Cell Renal Carcinoma

Interventions

DRUG

Pazopanib

Tablet 800mg qd til progression

DRUG

Everolimus

tablet 10 mg qd til progression

DRUG

Pazopanib

tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus

DRUG

Everolimus

tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus

DRUG

Everolimus

Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen

DRUG

Pazopanib

Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen

Sponsors & Collaborators

  • Netherlands Working Group on Immunotherapy of Oncology

    lead OTHER

Principal Investigators

  • E.E. Voest, MD/PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408004 on ClinicalTrials.gov